Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Vasily Mamonov"'
Autor:
Jerzy Windyga MD, PhD, Margarita Timofeeva MD, Oleksandra Stasyshyn MD, PhD, Vasily Mamonov MD, PhD, José Luis Lamas Castellanos MD, Toshko Lissitchkov MD, PhD, Krzysztof Chojnowski MD, PhD, Miranda Chapman BSc, Borislava G. Pavlova PhD, Srilatha Tangada PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Hemostatic management is essential for ensuring the safety of patients with hemophilia during surgery. This phase 3, prospective, uncontrolled trial, evaluated hemostatic efficacy, consumption, and safety of a recombinant factor IX concentrate, nonac
Externí odkaz:
https://doaj.org/article/7998488d886248d198a60d98265dfc0e
Autor:
Jerzy Windyga MD, PhD, Oleksandra Stasyshyn MD, PhD, Toshko Lissitchkov MD, PhD, Vasily Mamonov MD, PhD, Margit Serban MD, PhD, Luminita Rusen MD, PhD, Bettina Ploder MSc, Srilatha Tangada PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
This phase 3, prospective, open-label, multicenter, continuation study (NCT01286779) investigated the use of a recombinant factor IX (FIX), nonacog gamma (BAX 326, RIXUBIS ® ) in patients with severe or moderately severe hemophilia B. The study popu
Externí odkaz:
https://doaj.org/article/53acbf307856414a98abc07531c9dfd7
Autor:
Vasily Mamonov, Bruce Ewenstein, Jerzy Windyga, Srilatha Tangada, Jennifer Doralt, Ingrid Pabinger, Gerald Spotts, Werner Engl
Publikováno v:
Haemophilia
Introduction In patients with haemophilia A undergoing surgery, factor VIII (FVIII) replacement therapy by continuous infusion (CI) may offer an alternative to bolus infusion (BI). Aim To compare the perioperative haemostatic efficacy and safety of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7608ce3b154683b1689776d236db54d
https://doi.org/10.1111/hae.14219
https://doi.org/10.1111/hae.14219
Autor:
Liana Gercheva-Kyuchukova, Huy Van Nguyen, Tim Mant, Catherine Bagot, Baisong Mei, Qifeng Yu, Margaret V. Ragni, Craig Benson, Kate Madigan, Toshko Lissitchkov, K. John Pasi, Margarita Timofeeva, Pratima Chowdary, Pencho Georgiev, Vasily Mamonov
Publikováno v:
Journal of Thrombosis and Haemostasis
Background Fitusiran, an investigational small interfering RNA therapy, reduces antithrombin production to rebalance hemostasis in people with hemophilia A or B, with or without inhibitors. Objectives To evaluate the safety and efficacy of fitusiran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8c4dd37dee07aac554599d82ced9e17
https://pubmed.ncbi.nlm.nih.gov/33587824
https://pubmed.ncbi.nlm.nih.gov/33587824
Autor:
Margarita Timofeeva, Vasily Mamonov, Krzysztof Chojnowski, Jerzy Windyga, Srilatha Tangada, Oleksandra Stasyshyn, Miranda Chapman, Borislava G. Pavlova, José Luis Lamas Castellanos, Toshko Lissitchkov
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Clinical and Applied Thrombosis/Hemostasis
Clinical and Applied Thrombosis/Hemostasis
Hemostatic management is essential for ensuring the safety of patients with hemophilia during surgery. This phase 3, prospective, uncontrolled trial, evaluated hemostatic efficacy, consumption, and safety of a recombinant factor IX concentrate, nonac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42307c716b439374831e35c18bf59e5c
https://doaj.org/article/7998488d886248d198a60d98265dfc0e
https://doaj.org/article/7998488d886248d198a60d98265dfc0e
Autor:
Ploder Bettina, Jerzy Windyga, Srilatha Tangada, Margit Serban, L. Rusen, Toshko Lissitchkov, Vasily Mamonov, Oleksandra Stasyshyn
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Clinical and Applied Thrombosis/Hemostasis
Clinical and Applied Thrombosis/Hemostasis
This phase 3, prospective, open-label, multicenter, continuation study (NCT01286779) investigated the use of a recombinant factor IX (FIX), nonacog gamma (BAX 326, RIXUBIS®) in patients with severe or moderately severe hemophilia B. The study popula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::882267560528a45ab9fe6dbec437f598
https://doaj.org/article/53acbf307856414a98abc07531c9dfd7
https://doaj.org/article/53acbf307856414a98abc07531c9dfd7
Autor:
Aleksander B. Skotnicki, Svetlana Stankovic, Wilfried Seifert, Alex Veldman, Andrzej Hellmann, Anna Klukowska, Toshko Lissitchkov, Evgeny Buevich, Anna Dmoszynska, Liana Gercheva, Krystyna Zawilska, Vasily Mamonov, Kazimierz Kuliczkowski, Janusz Kloczko, Stefcho Goranov, Tatiana Chernova, Christine Joch
Publikováno v:
Thrombosis Research. 137:119-125
Introduction VONCENTO® (CSL Behring) is a plasma-derived, high-concentration, low-volume, high-purity concentrate, which contains a high level of von Willebrand factor (VWF) high-molecular-weight multimers and a VWF/factor VIII (FVIII) ratio of ~2.4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5c8ed55dc4a4ff69c7f8792f8170053
https://doi.org/10.1016/j.thromres.2015.10.014
https://doi.org/10.1016/j.thromres.2015.10.014
Autor:
Margaret V. Ragni, Michael Desmond Creagh, Akin Akinc, Inga Hegemann, Toshko Lissitchkov, Akshay Vaishnaw, K. John Pasi, Tim Mant, Pushkal Garg, Liana Gercheva-Kyuchukova, Margarita Timofeeva, Savita Rangarajan, Rashid S. Kazmi, Pencho Georgiev, Chang-Heok Soh, Steve Austin, David H. Bevan, Benny Sørensen, Charles R. M. Hay, Pratima Chowdary, Vasily Mamonov
Publikováno v:
The New England journal of medicine. 377(9)
BACKGROUND: Current hemophilia treatment involves frequent intravenous infusions of clotting factors, which is associated with variable hemostatic protection, a high treatment burden, and a risk of the development of inhibitory alloantibodies. Fitusi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b158e5da40bdace27505aab605a9b2d9
https://pubmed.ncbi.nlm.nih.gov/28691885
https://pubmed.ncbi.nlm.nih.gov/28691885
Autor:
Oleksandra Stasyshyn, Sandor Fritsch, Miranda Chapman, W.-Y. Wong, Jerzy Windyga, Vasily Mamonov, Toshko Lissitchkov, H. Ghandehari, Borislava G. Pavlova, Brigitt E. Abbuehl
Publikováno v:
Haemophilia. 20:651-658
Summary Haemostatic management of haemophilia B patients undergoing surgery is critical to patient safety. The aim of this ongoing prospective trial was to investigate the haemostatic efficacy and safety of a recombinant factor IX (rFIX) (Bax326) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e32b46421b42e6f6655cc405e134230d
https://doi.org/10.1111/hae.12419
https://doi.org/10.1111/hae.12419
Autor:
Areg Grigorian, Vasily Mamonov, S. V. Antunes, Norma Guzman-Becerra, S. Tangada, W.-Y. Wong, J. Phillips, Bruce M. Ewenstein, Oleksandra Stasyshyn
Publikováno v:
Haemophilia
Factor replacement therapy for the treatment of moderate to severe haemophilia A and B can be complicated by the production of inhibitory alloantibodies to factor VIII (FVIII) or factor IX. Treatment with the nanofiltered anti-inhibitor coagulant com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f555fd58cf27e81bda7f4aa09ede95cf
https://doi.org/10.1111/hae.12246
https://doi.org/10.1111/hae.12246